IP Library Granted Patent US 9,849,114
Granted Patent B2
US 9,849,114 · App. 15/168,432 · Granted Dec 26, 2017

Oxymetazoline for the treatment of ano-rectal disorders

Inventors: Nir Barak (Tel Aviv, IL); Howard Lawrence Rice (Tel Aviv, IL)
Assignee: RDD Pharma Ltd.
A61K31/4174A61K9/0031A61K31/4164A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,849,114
App. No.
15/168,432
Granted
Dec 26, 2017
Kind
B2
Abstract

Methods for treating fecal incontinence by administering to a subject in need thereof compositions including oxymetazoline as an active ingredient. Kits including compositions of oxymetazoline suitable for topical application, for the treatment of fecal incontinence.

Claims (9)

1. A method,

wherein the method treats fecal incontinence in a subject in need thereof,

wherein the method comprises: administering a therapeutically effective amount of a composition consisting essentially of oxymetazoline or a pharmaceutically acceptable salt thereof to the subject's anal cavity, to treat the fecal incontinence, wherein the composition consists essentially of 0.1% to 1% of oxymetazoline or the pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the pharmaceutically acceptable salt is oxymetazoline hydrochloride.

3. The method of claim 1 , wherein the composition includes at least one carrier, diluent, excipient, or combinations thereof.

4. The method of claim 1 , wherein the composition is one of a long acting composition, a controlled release composition, a slow release composition, a sustained release composition, a bioadhesive composition, and a mucoadhesive composition.

5. The method of claim 1 , wherein the composition is in a dosage form selected from the group consisting of: gel, cream, paste, spray suppository, mousse, emollient, powder, solution, suspension and foam.

6. The method of claim 1 , wherein the therapeutically effective amount of the composition consists essentially of 0.1% to 0.8% of oxymetazoline or the pharmaceutically acceptable salt thereof.

7. The method of claim 1 , wherein the therapeutically effective amount of the composition is sufficient to treat fecal incontinence in the subject for at least 4 hours.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 21, 2024
From: RDD PHARMA LTD.
To: EBRIS PHARMA CO.
Reel/Frame 067484/0347 →
CHANGE OF NAME Recorded May 21, 2024
From: EBRIS PHARMA CO.
To: INTERLUDE BIOPHARMA CO.
Reel/Frame 067484/0517 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 20, 2020
From: BARAK, NIR; RICE, HOWARD LAWRENCE
To: RDD PHARMA LTD.
Reel/Frame 053247/0915 →
Continuity (4)
Division 14063759 · Oct 25, 2013
Continuation PCTIL2012050148 · Apr 24, 2012
Provisional Application 61478949 · Apr 26, 2011
Related Publication 20160271110A1 · Sep 22, 2016